Q32 Bio Inc (QTTB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $260.64M
Last updated: Nov 17, 2026 at 11:06 AM ET
Q32 Bio Inc (QTTB) Stock Forecast
Analysts expect Q32 Bio (QTTB) to earn -$1.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $333330. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 150.0%.
- Fiscal year ending Dec 31, 2026
- -$1.40
- EPS consensus, revenue $333330
- Fiscal year ending Dec 31, 2027
- -$2.16
- EPS consensus, revenue $833330
- Next report
- May 3, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.40 | -$1.46 to -$1.36 | 7 | $333330 | N/A | 6 |
| Dec 31, 2027 | -$2.16 | -$3.15 to -$1.22 | 7 | $833330 | N/A | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.31 for the quarter ending Dec 31, 2026 to -$0.42 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.31 | -$0.36 to -$0.24 | 10 |
| Mar 31, 2027 | -$0.42 | -$0.43 to -$0.40 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.40 | -$1.50 | -$1.52 | -$1.49 | -$1.50 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.16 | -$2.27 | -$2.14 | -$1.82 | -$1.76 | N/A |
| Quarter ending Mar 31, 2027 | -$0.42 | -$0.41 | -$0.40 | -$0.34 | -$0.34 | N/A |
Frequently Asked Questions About QTTB
What is the QTTB stock forecast?
Consensus analyst estimates put Q32 Bio's EPS at -$1.40 for the fiscal year ending Dec 31, 2026, on revenue of $333330. The consensus rating from 7 analysts is Buy.
How do analysts rate QTTB stock?
Of 7 analysts covering Q32 Bio, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from QTTB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.40, with estimates from -$1.46 to -$1.36 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.16, with estimates from -$3.15 to -$1.22 from 7 analysts.
What revenue do analysts expect from Q32 Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $333330. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $833330.
How many analysts cover QTTB?
7 analysts rate Q32 Bio stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
QTTB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors